Avidity Partners Management’s Nuvectis Pharma NVCT Stock Holding History

Avidity Partners Management’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.68M	Buy	+200,000	New	+$2.24M	0.59%	22

Other funds holding NVCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Avidity Partners Management's NVCT Position: Q2 2026 in Review

Avidity Partners Management opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 200,000 shares worth $3.68M. The stake represents 0.59% of the portfolio and ranks #22 among its holdings.

75 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Avidity Partners Management held 200,000 shares of Nuvectis Pharma worth $3.68M as of Q2 2026.
Nuvectis Pharma was a new Avidity Partners Management position in Q2 2026.
Nuvectis Pharma made up 0.59% of Avidity Partners Management's portfolio in Q2 2026, its #22 holding.
75 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.